Cyclosporine plus eltrombopag in the treatment of aplastic anemia with or without antithymocyte immunoglobulin: A multicenter real‐world retrospective study
European Journal of Haematology · 2023
DOI: 10.1111/ejh.14021 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Haematology, 2023. Verfasst von Miao Chen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Hauptthemen laut MEDLINE: Cyclosporine, Anemia, Aplastic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: National Natural Science Foundation of China, CAMS Innovation Fund for Medical Sciences, National High Level Hospital Clinical Research Funding.
Abstract (Originalsprache)
Aims
To compare cyclosporine (CSA) combining eltrombopag (EPAG) with or without antithymocyte globulin (ATG) in aplastic anemia (AA) patients in the real world.
Methods
AA patients who received ATG combining CSA and EPAG (Group A) and CSA + EPAG (Group B) as front‐line treatment in 13 medical centers in China were enrolled. The efficacy and safety were compared.
Results
A total of 89 patients were enrolled with 51 patients in Group A and 38 patients in Group B. The 6‐month overall response (OR)/complete response (CR) was 73.3%/24.4% and 60.6%/27.3% in Groups A and B ( p > .1). For severe AA patients, the 6‐month OR was 74.1% versus 50% and 6‐month CR was 25.9% versus 20% in Groups A and B ( p > 0.1). Multivariate analysis showed gender affects the 6‐month OR with females better OR ( p = .017, OR 6.045, 95% CI: 1.377–26.546) and time from disease onset to treatment affected the 12‐month CR ( p = .026, OR 0.263, 95% CI: 0.081–0.852). No difference was found in side effects except ATG infusion reaction and serum sickness. Mortality was 7.8% in Group A and no patient died in Group B.
Conclusions
CSA + EPAG had a similar response and less side effects compared with standard immunosuppressive therapy + EPAG in newly diagnosed AA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- The First Hospital of Hebei Medical University, Shijiazhuang, China.
- The Affiliated Hospital of Qingdao University, Qingdao, China.
- HanDan Central Hospital, Handan, China.
- Dongfang Hospital Beijing University of Chinese Medicine, Beijing, China.
- Qingdao Central Hospital, Qingdao Central Medical Group, Qingdao, China.
ORCID-Profile: Miao Chen
Förderung
- National Natural Science Foundation of China
- CAMS Innovation Fund for Medical Sciences
- National High Level Hospital Clinical Research Funding
Zitieren
APA
Chen, M., Liu, Q., Gao, Y., Suo, X., Ding, X., Wang, L., Li, L., Shao, Y., Gao, D., Sun, W., Tan, Y., Wang, W., Ye, F., & Han, B. (2023). Cyclosporine plus eltrombopag in the treatment of aplastic anemia with or without antithymocyte immunoglobulin: A multicenter real‐world retrospective study. European Journal of Haematology. https://doi.org/10.1111/ejh.14021
Vancouver
Chen M, Liu Q, Gao Y, Suo X, Ding X, Wang L, et al. Cyclosporine plus eltrombopag in the treatment of aplastic anemia with or without antithymocyte immunoglobulin: A multicenter real‐world retrospective study. European Journal of Haematology. 2023. doi:10.1111/ejh.14021
BibTeX
@article{Chen2023,
author = {Chen, Miao and Liu, Qingchi and Gao, Yan and Suo, Xiaohui and Ding, Xiaoqing and Wang, Ling and Li, Lihong and Shao, Yingqi and Gao, Da and Sun, Wanling and Tan, Yehui and Wang, Wei and Ye, Fang and Han, Bing},
title = {Cyclosporine plus eltrombopag in the treatment of aplastic anemia with or without antithymocyte immunoglobulin: A multicenter real‐world retrospective study},
journal = {European Journal of Haematology},
year = {2023},
doi = {10.1111/ejh.14021}
}
EUVIMED